Status:
COMPLETED
Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia
Lead Sponsor:
CSL Limited
Conditions:
Acute Myeloid Leukemia (AML)
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Acute myeloid leukemia (AML) is a heterogeneous group of diseases characterized by uncontrolled proliferation of the myeloid line of white blood cells and impaired production of normal blood cells. If...
Eligibility Criteria
Inclusion
- Clinical diagnosis of acute myeloid leukemia
- Recent bone marrow biopsy
- Prior treatment or medically unfit for standard therapy
Exclusion
- Peripheral blood blast count \> 30 x 109/L, or rapidly progressive AML
- Previous solid organ transplant
- Active GvHD or immunosuppression
- Concurrent treatment with other anti-cancer therapy
- Active infections
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00401739
Start Date
December 1 2006
End Date
September 1 2009
Last Update
September 16 2009
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Westmead Hospital
Westmead, New South Wales, Australia, 2145
2
Royal Brisbane and Women's Hospital
Brisbane, Queensland, Australia, 4029
3
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia, 4102
4
Institute of Medical & Veterinary Science
Adelaide, South Australia, Australia, 5000